|

Oral repotrectinib (TPX-0005) Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Oral repotrectinib (TPX-0005) capsules, Oral repotrectinib (TPX-0005) oral suspension, repotrectinib

Pipeline

Phase 1/2: 2

Top Sponsors

  • Turning Point Therapeutics, Inc.2

Indications

  • Locally Advanced Solid Tumors2
  • Metastatic Solid Tumors2
  • Cancer2
  • Primary CNS Tumors1
  • Lymphoma1

Duarte, California1 trial

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Local Institution - 2129

Phase 1/2

Los Angeles, California1 trial

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Children's Hospital Los Angeles

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.